SciClone Invests $3 Million in Soligenix; Finalizes China Oral Mucositis Drug In-licensing

SciClone Pharma, a US company that in-licenses drugs for the China market, struck a final deal for rights to a novel treatment for oral mucositis from Soligenix of New Jersey. In return for a $3 million investment into Soligenix, SciClone will have rights to SGX942 in China including Hong Kong and Macau, plus Taiwan, South Korea and Vietnam. The two companies have been collaborating for three years. In 2013, SciClone gave Soligenix access to trial data from its failed oral mucositis treatment in return for China rights. At the end of 2015, SciClone started developing SGX942 in China. The $3 million investment and the expanded list of countries is new information. More details.... Stock Symbols: (NSDQ: SCLN) (OTC: SNGX) Share this with colleagues: // //